Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. ProMIS Neurosciences, Inc.
  6. News
  7. Summary
    PMN   CA74346M1095

PROMIS NEUROSCIENCES, INC.

(PMN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Update: ProMIS Neurosciences Up 8.1% As Says initiated Commercialization of COVID-19 Serology Assay

05/25/2021 | 09:47am EDT


ę MT Newswires 2021
All news about PROMIS NEUROSCIENCES, INC.
08/02PROMIS NEUROSCIENCES : Presentations at 2021 Alzheimer's Association Internation..
PU
07/22PROMIS NEUROSCIENCES : to Present at 2021 Alzheimer's Association International ..
AQ
07/08PROMIS NEUROSCIENCES : Files Final Base Shelf Prospectus
MT
07/08ProMIS Neurosciences Obtains Receipt for Final Base Shelf Prospectus
GL
07/02PROMIS NEUROSCIENCES : Announces Results of Annual Meeting of Shareholders
PU
06/09PROMIS NEUROSCIENCES : congratulates Biogen on FDA accelerated approval of aduca..
AQ
06/08PROMIS NEUROSCIENCES : congratulates Biogen on FDA accelerated approval of aduca..
PU
06/07PROMIS NEUROSCIENCES : up 30% on FDA Approval of Biogen's Aducanumab
MT
06/03PROMIS NEUROSCIENCES : Files preliminary short form base shelf prospectus
PU
05/27ProMIS Neurosciences, Inc. Appoints Dr. David Wishart as Chief Physics Office..
CI
More news
Financials
Sales 2020 0,00 M 0,00 M 0,00 M
Net income 2020 -5,66 M -4,52 M -4,52 M
Net cash 2020 1,07 M 0,86 M 0,86 M
P/E ratio 2020 -3,96x
Yield 2020 -
Capitalization 59,7 M 47,8 M 47,7 M
EV / Sales 2019 37 534x
EV / Sales 2020 15 614x
Nbr of Employees -
Free-Float 81,2%
Chart PROMIS NEUROSCIENCES, INC.
Duration : Period :
ProMIS Neurosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROMIS NEUROSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Managers and Directors
Elliot Goldstein President, Chief Executive Officer & Director
Daniel E. Geffken Chief Financial Officer
Eugene Williams Executive Chairman
Neil R. Cashman Director & Chief Scientific Officer
William W. Wyman Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PROMIS NEUROSCIENCES, INC.95.00%48
GILEAD SCIENCES, INC.17.22%85 648
BIONTECH SE317.33%79 303
WUXI APPTEC CO., LTD.36.10%59 516
REGENERON PHARMACEUTICALS18.94%59 505
VERTEX PHARMACEUTICALS-16.09%52 296